Arthur Weiss, M.D., Ph.D., is a pioneer in cell biology and signal transduction. Dr. Weiss is a Howard Hughes Medical Institute Investigator and Ephraim P. Engleman Distinguished Professor, University of California San Francisco. He has previously served as the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences, and the Institute of Medicine. Dr. Weiss received his B.A. at the Johns Hopkins University and his M.D. and Ph.D. from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Robert Tjian, Ph.D., has served as the Chair of Nurix’s Scientific Advisory Board since October 2020 and was a member of the company’s board of directors from November 2016 through October 2020. Dr. Tjian is currently a Discovery Partner at The Column Group, a healthcare venture capital firm, where he has worked since September 2016. Prior to joining The Column Group, Dr. Tjian served as President of the Howard Hughes Medical Institute from 2009 to September 2016. Prior to that, Dr. Tjian served in a variety of leadership roles as a faculty member at the University of California, Berkeley, including as Director of the Berkeley Stem Cell Center, Faculty Director of the Li Ka Shing Center for Biomedical and Health Sciences, and Head of the Siebel Stem Institute. Dr. Tjian currently holds the Li Ka Shing Chancellor’s Chair in Biology at the University of California, Berkeley and serves as a scientific advisor to the Chan Zuckerberg Initiative and Chan Zuckerberg BioHub. Dr. Tjian holds a B.A. from University of California, Berkeley in Biochemistry and a Ph.D. in Molecular Biology from Harvard University.